Virulence-Attenuated Salmonella Engineered to Secrete Immunomodulators Reduce Tumour Growth and Increase Survival in An Autochthonous Mouse Model of Breast Cancer.
J Drug Target. 2020 Nov 12;:1-33
Authors: Augustin LB, Milbauer L, Hastings SE, Leonard AS, Saltzman DA, Schottel JL
The ultimate goal of bacterial based cancer therapy is to achieve non-toxic penetration and colonization of the tumour microenvironment. To overcome this efficacy-limiting toxicity of anticancer immunotherapy, we have tested a therapy comprised of systemic delivery of a vascular disrupting agent to induce intratumoral necrotic space, cannabidiol to temporarily inhibit angiogenesis and acute inflammation, and a strain of Salmonella Typhimurium that was engineered for nontoxic colonization and expression of immunomodulators within the tumour microenvironment. This combination treatment strategy was administered to transgenic mice burdened with autochthonous mammary gland tumours and demonstrated a statistically significant 64% slower tumour growth and a 25% increase in mean survival time compared to control animals without treatment. These experiments were accomplished with minimal toxicity as measured by less than 7% weight loss and a return to normal weight gain within three days following intravenous administration of the bacteria. Thus, nontoxic, robust colonization of the microenvironment was achieved to produce a significant antitumor effect.
PMID: 33183080 [PubMed – as supplied by publisher]